Objectives: To describe dosing practices for amantadine hydrochloride and related adverse effects among children and young adults with traumatic brain injury (TBI) admitted to pediatric inpatient rehabilitation units. Setting: Eight pediatric acute inpatient rehabilitation units located throughout the United States comprising the Pediatric Brain Injury Consortium. Participants: Two-hundred thirty-four children and young adults aged 2 months to 21 years with TBI. Design: Retrospective data revie. Main Outcome Measures: Demographic variables associated with the use of amantadine, amantadine dose, and reported adverse effects. Results: Forty-nine patients (21%) aged 0.9 to 20 years received amantadine during inpatient rehabilitation. Forty-five percent of patients admitted